ArticleJournal of cellular and molecular medicine2020
Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4.
Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- In vivo Effects of Acute Inflammatory Responses on Dopaminergic Receptor Expression in Leukocytes and Marginal Effects of Hypoxia Pretreatment.Neuroimmunomodulation · 2026Article
- Predicting Immune Flares in Untreated Chronic Hepatitis B Patients Using Novel Risk Factors and the FLARE-B Score.Digestive diseases and sciences · 2025Article
- Dynamics of HBsAb persistence and associated BCR IgG-H CDR3 repertoire features in ultra-high versus extremely low responders to HBV vaccination.Frontiers in immunology · 2025Article
- Activated circulating T follicular helper 17 cells positively correlated with anti-HBV humoral immunity in chronic hepatitis B patients.Frontiers in microbiology · 2025Article
- Viral Hepatitis: Host Immune Interaction, Pathogenesis and New Therapeutic Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Bilobalide attenuates lipopolysaccharide‑induced HepG2 cell injury by inhibiting TLR4‑NF‑κB signaling via the PI3K/Akt pathway.Experimental and therapeutic medicine · 2024Article
- Plerixafor and resatorvid inhibit hepatitis B virusFrontiers in cellular and infection microbiology · 2023Article
- Hepatitis B functional cure and immune response.Frontiers in immunology · 2022Review
- Toll-like Receptors in Viral Encephalitis.Viruses · 2021Review
- Hepatitis B virus-induced hyperactivation of B cells in chronic hepatitis B patients via TLR4.Journal of cellular and molecular medicine · 2020Article
- The Role of IL-35 in the Pathophysiological Processes of Liver Disease.Frontiers in pharmacology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cell hyperactivation and functional impairment were identified from patients with chronic hepatitis B virus (CHB) infection; however, the underlying mechanism remains unknown. Here, we aim to elucidate the mechanisms responsible for B cell hyperactivation during HBV infection. Peripheral CD19
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.